beta

AKCA

Akcea Therapeutics Inc.

Akca

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

02-26-2019 after market close 11-05-2018 after market close 05-03-2018 after market close 02-26-2018 after market close 11-06-2017 after market close 08-08-2017
Actual EPS -0.79 -0.73 -0.44 -0.26 -0.18 -0.27
Consensus EPS -0.7 -0.97 -0.34 -0.23 -0.21
Estimated EPS -0.7 -0.97 -0.34 -0.23 -0.21
Number of Estimates 3 3 3 3 3
EPS Surprise -$0.09 $0.24 -$0.10 -$0.03 $0.03

Stats

Summary

Akcea Therapeutics Inc is a late stage biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders.

Market Cap: 1.29 Billion

Primary Exchange: Nasdaq Global Select

Website: http://www.akceatx.com

Shares Outstanding: 66.5 Million

Float: 66.5 Million

Dividend: 0.0 (0.0%)

Beta: -0.614617

Sector: Healthcare

Industry: Biotechnology

Short Interest (Jan 12, 2018): 3.82 Million

Ethical Flags

Animal testing

Longest drawdown: 212 trading days

From: 2018-08-07 To: 2019-06-12

Lowest Point:

Pfizer Nabs Regulatory Approval For Tafamidis, An FDA First Is Achieved

via: SeekingAlpha at 2019-05-20 13:58:00:000

Pfizer ( PFE ) was able to obtain FDA approval for its drugs by the name of Vyndaqel and Vyndamax (tafamidis) to treat patients with transthyretin amyloid cardiomyopathy. This is a good approval for the company because it has given itself a great opportunity to target a space with no competi… read more...

Pfizer Nabs Regulatory Approval For Tafamidis, An FDA First Is Achieved

via: SeekingAlpha at 2019-05-20 13:58:00:000

Pfizer ( PFE ) was able to obtain FDA approval for its drugs by the name of Vyndaqel and Vyndamax (tafamidis) to treat patients with transthyretin amyloid cardiomyopathy. This is a good approval for the company because it has given itself a great opportunity to target a space with no competi… read more...

Pfizer Nabs Regulatory Approval For Tafamidis, An FDA First Is Achieved

via: SeekingAlpha at 2019-05-20 13:58:00:000

Pfizer ( PFE ) was able to obtain FDA approval for its drugs by the name of Vyndaqel and Vyndamax (tafamidis) to treat patients with transthyretin amyloid cardiomyopathy. This is a good approval for the company because it has given itself a great opportunity to target a space with no competi… read more...

Akcea Therapeutics, Inc. (AKCA) CEO Paula Soteropoulos on Q1 2019 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-05-08 19:31:33:000

Akcea Therapeutics, Inc. (AKCA) Q1 2019 Earnings Conference Call May 08, 2019 4:30 PM ET Company Participants Kathleen Gallagher - Vice President of Corporate Communications & Investor Relations Paula Soteropoulos - Chief Executive Officer Sarah Boyce - President Michael Ma… read more...

Akcea Therapeutics, Inc. (AKCA) CEO Paula Soteropoulos on Q1 2019 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-05-08 19:31:33:000

Akcea Therapeutics, Inc. (AKCA) Q1 2019 Earnings Conference Call May 08, 2019 4:30 PM ET Company Participants Kathleen Gallagher - Vice President of Corporate Communications & Investor Relations Paula Soteropoulos - Chief Executive Officer Sarah Boyce - President Michael Ma… read more...

Akcea Therapeutics, Inc. (AKCA) CEO Paula Soteropoulos on Q1 2019 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-05-08 19:31:33:000

Akcea Therapeutics, Inc. (AKCA) Q1 2019 Earnings Conference Call May 08, 2019 4:30 PM ET Company Participants Kathleen Gallagher - Vice President of Corporate Communications & Investor Relations Paula Soteropoulos - Chief Executive Officer Sarah Boyce - President Michael Ma… read more...

Biotech News Recap: Merck Announces Yet Another Successful Readout For A Key Asset

via: SeekingAlpha at 2019-05-08 16:17:46:000

Merck & Co ( MRK ) - The company announced results from the phase 2 study of V114 (15-valent pneumococcal conjugate vaccine) as compared to currently available 13-valent pneumococcal conjugate vaccine in healthy infants 6-12 weeks of age. The primary endpoint was met by demonstrating n… read more...

Biotech News Recap: Merck Announces Yet Another Successful Readout For A Key Asset

via: SeekingAlpha at 2019-05-08 16:17:46:000

Merck & Co ( MRK ) - The company announced results from the phase 2 study of V114 (15-valent pneumococcal conjugate vaccine) as compared to currently available 13-valent pneumococcal conjugate vaccine in healthy infants 6-12 weeks of age. The primary endpoint was met by demonstrating n… read more...

Biotech News Recap: Merck Announces Yet Another Successful Readout For A Key Asset

via: SeekingAlpha at 2019-05-08 16:17:46:000

Merck & Co ( MRK ) - The company announced results from the phase 2 study of V114 (15-valent pneumococcal conjugate vaccine) as compared to currently available 13-valent pneumococcal conjugate vaccine in healthy infants 6-12 weeks of age. The primary endpoint was met by demonstrating n… read more...

Akcea Q1 revenues up big on license fee from Novartis

via: SeekingAlpha at 2019-05-08 12:46:49:000

Akcea Therapeutics (NASDAQ: AKCA ) Q1 results ($M): Revenues: 163.8 (+857.9%) due to a $150M license fee from Novartis for AKCEA-APO(a)-Lrx. More news on: Akcea Therapeutics, Inc., Healthcare stocks news, Earnings news and commentary, Read more … read more...

Akcea Therapeutics misses on revenue

via: SeekingAlpha at 2019-05-08 12:39:38:000

Akcea Therapeutics (NASDAQ: AKCA ): Q1 Non-GAAP net income of $45.7M. More news on: Akcea Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

Notable earnings after Wednesday's close

via: SeekingAlpha at 2019-05-07 13:35:58:000

AAOI , AIMT , AKCA , ALB , ANGI , APLE , ARNA , ASRT , AXGN , BIO , BREW , CCMP , CECO , CNDT , COLL , CPA , CTL , CVNA , CW , CWH , CXW , DAR , DHT , DIS , DRH , DVAX , ECPG , EGAN , ELF , ENV , ET , ETSY , EVRG , EZPW , FLNT , FNV , FOSL , FOXA , FTK… read more...

Akcea Therapeutics Q1 2019 Earnings Preview

via: SeekingAlpha at 2019-05-07 13:35:13:000

Akcea Therapeutics (NASDAQ: AKCA ) is scheduled to announce Q1 earnings results on Wednesday, May 8th, after market close. The consensus EPS Estimate is $0.98 and the consensus Revenue Estimate is $171.4M (+901.8% Y/Y). Over the last 1 year, akca has beaten EPS estimates 25% of … read more...

Akcea's Waylivra conditionally OK'd in Europe for rare triglyceride disorder

via: SeekingAlpha at 2019-05-07 05:01:04:000

As expected, the European Commission has conditionally approved Akcea Therapeutics' (NASDAQ: AKCA ) WAYLIVRA (volanesorsen) as an adjunct to diet in adults with familial chylomicronemia syndrome (FCS), a rare inherited disorder characterized by excessive blood triglyceride levels, who… read more...

Alnylam Posts Another Encouraging Quarter Early In Onpattro's Launch

via: SeekingAlpha at 2019-05-02 06:53:12:000

As difficult as it is to get a drug from the lab to the market, that's only part of the formula for success for biotechs - successful commercialization is every bit as important, and commercialization can have its own frustrating bumps along the road. While I see nothing wrong with the launch … read more...

Alnylam Posts Another Encouraging Quarter Early In Onpattro's Launch

via: SeekingAlpha at 2019-05-02 06:53:12:000

As difficult as it is to get a drug from the lab to the market, that's only part of the formula for success for biotechs - successful commercialization is every bit as important, and commercialization can have its own frustrating bumps along the road. While I see nothing wrong with the launch … read more...

Alnylam Posts Another Encouraging Quarter Early In Onpattro's Launch

via: SeekingAlpha at 2019-05-02 06:53:12:000

As difficult as it is to get a drug from the lab to the market, that's only part of the formula for success for biotechs - successful commercialization is every bit as important, and commercialization can have its own frustrating bumps along the road. While I see nothing wrong with the launch … read more...

Disney+ And Bank Majors Step Out (Stocks To Watch Podcast)

via: SeekingAlpha at 2019-04-07 03:37:15:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c… read more...

Disney+ And Bank Majors Step Out (Stocks To Watch Podcast)

via: SeekingAlpha at 2019-04-07 03:37:15:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c… read more...

Disney+ And Bank Majors Step Out (Stocks To Watch Podcast)

via: SeekingAlpha at 2019-04-07 03:37:15:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c… read more...

Stocks To Watch: Disney+ And Bank Majors Step Out

via: SeekingAlpha at 2019-04-06 04:39:00:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. The week ahead sees a heavy dose of healthcare companies presenting at investor con… read more...

European advisory group backs Akcea's Waylivra for rare triglyceride disorder

via: SeekingAlpha at 2019-03-01 03:05:41:000

The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending conditional approval for Akcea Therapeutics' (NASDAQ: AKCA ) Waylivra (volanesorsen) for the treatment of familial chylomicronemia syndrome (FCS), a rare inherited disorder characterized by exce… read more...

European advisory group backs Akcea's Waylivra for rare triglyceride disorder

via: SeekingAlpha at 2019-03-01 03:05:41:000

The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending conditional approval for Akcea Therapeutics' (NASDAQ: AKCA ) Waylivra (volanesorsen) for the treatment of familial chylomicronemia syndrome (FCS), a rare inherited disorder characterized by exce… read more...

European advisory group backs Akcea's Waylivra for rare triglyceride disorder

via: SeekingAlpha at 2019-03-01 03:05:41:000

The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending conditional approval for Akcea Therapeutics' (NASDAQ: AKCA ) Waylivra (volanesorsen) for the treatment of familial chylomicronemia syndrome (FCS), a rare inherited disorder characterized by exce… read more...

European advisory group backs Akcea's Waylivra for rare triglyceride disorder

via: SeekingAlpha at 2019-03-01 03:05:41:000

The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending conditional approval for Akcea Therapeutics' (NASDAQ: AKCA ) Waylivra (volanesorsen) for the treatment of familial chylomicronemia syndrome (FCS), a rare inherited disorder characterized by exce… read more...

European advisory group backs Akcea's Waylivra for rare triglyceride disorder

via: SeekingAlpha at 2019-03-01 03:05:41:000

The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending conditional approval for Akcea Therapeutics' (NASDAQ: AKCA ) Waylivra (volanesorsen) for the treatment of familial chylomicronemia syndrome (FCS), a rare inherited disorder characterized by exce… read more...

Akcea Therapeutics (AKCA) CEO Paula Soteropoulos on Q4 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-02-26 21:24:04:000

Akcea Therapeutics (AKCA) Q4 2018 Results Earnings Conference Call February 26, 2019, 04:30 PM ET Company Participants Kathleen Gallagher - Vice President of Investor Relations and Corporate Communications Paula Soteropoulos - Chief Executive Officer Sarah Boyce - President Jef… read more...

Akcea Therapeutics (AKCA) CEO Paula Soteropoulos on Q4 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-02-26 21:24:04:000

Akcea Therapeutics (AKCA) Q4 2018 Results Earnings Conference Call February 26, 2019, 04:30 PM ET Company Participants Kathleen Gallagher - Vice President of Investor Relations and Corporate Communications Paula Soteropoulos - Chief Executive Officer Sarah Boyce - President Jef… read more...

Akcea Therapeutics 2018 Q4 - Results - Earnings Call Slides

via: SeekingAlpha at 2019-02-26 16:57:39:000

The following slide deck was published by Akcea Therapeutics in conjunction with their 2018 Q4 earnings Read more … read more...

Akcea Therapeutics misses by $0.06, misses on revenue

via: SeekingAlpha at 2019-02-26 16:15:58:000

Akcea Therapeutics (NASDAQ: AKCA ): Q4 GAAP EPS of -$0.79 misses by $0.06 . More news on: Akcea Therapeutics, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Notable earnings after Tuesday's close

via: SeekingAlpha at 2019-02-25 17:35:32:000

AAXN , ACAD , AKCA , ARNA , AXGN , BGS , BNFT , CERS , CLGX , CPE , CSGP , CW , DRQ , DVAX , ELF , ENPH , EOG , EVH , FOXF , FRPT , FTR , GWPH , HEI , HPR , HURN , HY , ICFI , IMAX , IMMR , INGN , INN , INSP , JAZZ , JBGS , MASI , MED , MELI , MGRC , M… read more...

Midday Gainers / Losers

via: SeekingAlpha at 2019-02-25 12:46:37:000

Gainers: China Internet Nationwide Financial Services (NASDAQ: CIFS ) +137% . Spark Therapeutics (NASDAQ: ONCE ) +120% . Clementia Pharmaceuticals (NASDAQ: CMTA ) +74% . uniQure N.V. (NASDAQ: QURE ) +30% . Titan Pharmaceuticals (NASDAQ: TTNP ) +27% . CRISPR Therapeutics AG (NASD… read more...

Novartis opts in on Akcea lipoprotein candidate

via: SeekingAlpha at 2019-02-25 08:25:04:000

Novartis (NYSE: NVS ) has exercised its option to in-license Akcea Therapeutics' (NASDAQ: AKCA ) AKCEA-APO(a)-L Rx for patients with elevated levels of lipoprotein(a), or Lp(a), and established cardiovascular disease. Novartis will development the antisense drug under the moniker TQJ230. … read more...

Biotech Bonanza: The Mergers And Acquisitions Theme

via: SeekingAlpha at 2019-02-13 14:55:11:000

Biotech Pulse Biotech tumbled off a steep ski slope in the last quarter, and at the December low, the Nasdaq Biotechnology Index ( IBB ) had declined -28%, while the S&P Biotech Select Index ( XBI ) a whopping -36%. But it seems biotechs were able to regain their composure at the lows an… read more...

Biotech Bonanza: The Mergers And Acquisitions Theme

via: SeekingAlpha at 2019-02-13 14:55:11:000

Biotech Pulse Biotech tumbled off a steep ski slope in the last quarter, and at the December low, the Nasdaq Biotechnology Index ( IBB ) had declined -28%, while the S&P Biotech Select Index ( XBI ) a whopping -36%. But it seems biotechs were able to regain their composure at the lows an… read more...

Biotech Bonanza: The Mergers And Acquisitions Theme

via: SeekingAlpha at 2019-02-13 14:55:11:000

Biotech Pulse Biotech tumbled off a steep ski slope in the last quarter, and at the December low, the Nasdaq Biotechnology Index ( IBB ) had declined -28%, while the S&P Biotech Select Index ( XBI ) a whopping -36%. But it seems biotechs were able to regain their composure at the lows an… read more...

Disney, Alphabet And Super Bowl Players (Stocks To Watch Podcast)

via: SeekingAlpha at 2019-02-03 07:35:41:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions, and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday, look f… read more...

Disney, Alphabet And Super Bowl Players (Stocks To Watch Podcast)

via: SeekingAlpha at 2019-02-03 07:35:41:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions, and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday, look f… read more...

Disney, Alphabet And Super Bowl Players (Stocks To Watch Podcast)

via: SeekingAlpha at 2019-02-03 07:35:41:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions, and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday, look f… read more...

Stocks To Watch: Disney, Alphabet And Super Bowl Players

via: SeekingAlpha at 2019-02-02 08:39:18:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. The market is moving in the right direction after some cooling off of Washington-Be… read more...

Ionis Hits Huntington's Milestone, Still A Buy

via: SeekingAlpha at 2019-02-01 11:35:18:000

Ionis Pharmaceuticals ( IONS ) is a biotechnology pharmaceutical company with commercial revenue, a large pipeline of RNA-based therapies, and an extensive partner network. Ionis licensed a therapy for Huntington's disease to Roche (RHHBY). On January 28, Ionis and Roche announced the fi… read more...

Pfizer Looks To Move Tafamidis Forward With Priority Review

via: SeekingAlpha at 2019-01-22 11:27:05:000

Recently, Pfizer ( PFE ) announced that it had successfully submitted both its New Drug Applications ((NDA)) for tafamidis. The two applications are for each version of the drug being approved to treat patients with a rare disease known as transthyretin amyloid cardiomyopathy (ATTR-CM). … read more...

Pfizer Looks To Move Tafamidis Forward With Priority Review

via: SeekingAlpha at 2019-01-22 11:27:05:000

Recently, Pfizer ( PFE ) announced that it had successfully submitted both its New Drug Applications ((NDA)) for tafamidis. The two applications are for each version of the drug being approved to treat patients with a rare disease known as transthyretin amyloid cardiomyopathy (ATTR-CM). … read more...

Pfizer Looks To Move Tafamidis Forward With Priority Review

via: SeekingAlpha at 2019-01-22 11:27:05:000

Recently, Pfizer ( PFE ) announced that it had successfully submitted both its New Drug Applications ((NDA)) for tafamidis. The two applications are for each version of the drug being approved to treat patients with a rare disease known as transthyretin amyloid cardiomyopathy (ATTR-CM). … read more...

Does The Bull Survive? Stock Market Outlook 2019

via: SeekingAlpha at 2019-01-11 17:01:16:000

Market Pulse The year 2018 will be remembered as the year when downside volatility thundered into the market in striking contrast to 2017 when stock market volatility was so meek that it subsided to a level below that of bonds for the first time. The final month of 2018 was different. The … read more...

Does The Bull Survive? Stock Market Outlook 2019

via: SeekingAlpha at 2019-01-11 17:01:16:000

Market Pulse The year 2018 will be remembered as the year when downside volatility thundered into the market in striking contrast to 2017 when stock market volatility was so meek that it subsided to a level below that of bonds for the first time. The final month of 2018 was different. The … read more...

Does The Bull Survive? Stock Market Outlook 2019

via: SeekingAlpha at 2019-01-11 17:01:16:000

Market Pulse The year 2018 will be remembered as the year when downside volatility thundered into the market in striking contrast to 2017 when stock market volatility was so meek that it subsided to a level below that of bonds for the first time. The final month of 2018 was different. The … read more...

Does The Bull Survive? Stock Market Outlook 2019

via: SeekingAlpha at 2019-01-11 17:01:16:000

Market Pulse The year 2018 will be remembered as the year when downside volatility thundered into the market in striking contrast to 2017 when stock market volatility was so meek that it subsided to a level below that of bonds for the first time. The final month of 2018 was different. The … read more...

Does The Bull Survive? Stock Market Outlook 2019

via: SeekingAlpha at 2019-01-11 17:01:16:000

Market Pulse The year 2018 will be remembered as the year when downside volatility thundered into the market in striking contrast to 2017 when stock market volatility was so meek that it subsided to a level below that of bonds for the first time. The final month of 2018 was different. The … read more...

Biotech Bonanza: 2019 Outlook On An Uphill Battle

via: SeekingAlpha at 2018-12-20 14:47:33:000

Biotech Pulse The stock market was on track for a solid double-digit return performance in 2018, until it entered the final quarter. The performance cart has been rattling ever since as the stock market's perception of risk has risen dramatically, leading to a sharp erosion of returns. While… read more...

Biotech Bonanza: 2019 Outlook On An Uphill Battle

via: SeekingAlpha at 2018-12-20 14:47:33:000

Biotech Pulse The stock market was on track for a solid double-digit return performance in 2018, until it entered the final quarter. The performance cart has been rattling ever since as the stock market's perception of risk has risen dramatically, leading to a sharp erosion of returns. While… read more...

Biotech Bonanza: 2019 Outlook On An Uphill Battle

via: SeekingAlpha at 2018-12-20 14:47:33:000

Biotech Pulse The stock market was on track for a solid double-digit return performance in 2018, until it entered the final quarter. The performance cart has been rattling ever since as the stock market's perception of risk has risen dramatically, leading to a sharp erosion of returns. While… read more...

A Sluggish Start With Onpattro Is Not What Alnylam Shareholders Needed

via: SeekingAlpha at 2018-11-20 05:21:30:000

Theres not much any company can do about a bad tape, but Alnylam ( ALNY ) has seen sentiment sour pretty sharply since late 2017 despite the approval and launch of its first drug Onpattro. Between worries about greater competition (moreso from Pfizer ( PFE ) than Ionis ( IONS )/ … read more...

A Sluggish Start With Onpattro Is Not What Alnylam Shareholders Needed

via: SeekingAlpha at 2018-11-20 05:21:30:000

Theres not much any company can do about a bad tape, but Alnylam ( ALNY ) has seen sentiment sour pretty sharply since late 2017 despite the approval and launch of its first drug Onpattro. Between worries about greater competition (moreso from Pfizer ( PFE ) than Ionis ( IONS )/ … read more...

A Sluggish Start With Onpattro Is Not What Alnylam Shareholders Needed

via: SeekingAlpha at 2018-11-20 05:21:30:000

Theres not much any company can do about a bad tape, but Alnylam ( ALNY ) has seen sentiment sour pretty sharply since late 2017 despite the approval and launch of its first drug Onpattro. Between worries about greater competition (moreso from Pfizer ( PFE ) than Ionis ( IONS )/ … read more...

Akcea up 3% on positive AKCEA-APO(a)-Lrx data

via: SeekingAlpha at 2018-11-12 14:08:41:000

Akcea Therapeutics ( AKCA +2.9% ) is up on below-average volume on the heels of its announcement of positive results from a Phase 2 clinical trial evaluating antisense drug AKCEA-APO(a)-Lrx in patients with established cardiovascular disease (CVD) and elevated levels of lipoprotein(a),… read more...

Akcea up 3% on positive AKCEA-APO(a)-Lrx data

via: SeekingAlpha at 2018-11-12 14:08:41:000

Akcea Therapeutics ( AKCA +2.9% ) is up on below-average volume on the heels of its announcement of positive results from a Phase 2 clinical trial evaluating antisense drug AKCEA-APO(a)-Lrx in patients with established cardiovascular disease (CVD) and elevated levels of lipoprotein(a),… read more...

Akcea up 3% on positive AKCEA-APO(a)-Lrx data

via: SeekingAlpha at 2018-11-12 14:08:41:000

Akcea Therapeutics ( AKCA +2.9% ) is up on below-average volume on the heels of its announcement of positive results from a Phase 2 clinical trial evaluating antisense drug AKCEA-APO(a)-Lrx in patients with established cardiovascular disease (CVD) and elevated levels of lipoprotein(a),… read more...

All Eyes On Walmart, Volkswagen And A Jedi Contract (Stocks To Watch Podcast)

via: SeekingAlpha at 2018-11-11 08:07:42:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions, and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday, look fo… read more...

Stocks To Watch: All Eyes On Walmart, Volkswagen And A Jedi Contract

via: SeekingAlpha at 2018-11-10 09:13:00:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. We are about 90% of the way through the earnings seasons, but a couple of heavy hit… read more...

Akcea Therapeutics (AKCA) CEO Paula Soteropoulos on Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-11-05 20:52:04:000

Akcea Therapeutics (AKCA) Q3 2018 Earnings Conference Call November 05, 2018, 04:30 PM ET Executives Kathleen Gallagher - Vice President of Investor Relations and Corporate Communications Paula Soteropoulos - Chief Executive Officer Mike MacLean - Chief Financial Officer Sarah … read more...

Akcea Therapeutics (AKCA) CEO Paula Soteropoulos on Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-11-05 20:52:04:000

Akcea Therapeutics (AKCA) Q3 2018 Earnings Conference Call November 05, 2018, 04:30 PM ET Executives Kathleen Gallagher - Vice President of Investor Relations and Corporate Communications Paula Soteropoulos - Chief Executive Officer Mike MacLean - Chief Financial Officer Sarah … read more...

Akcea Therapeutics (AKCA) CEO Paula Soteropoulos on Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-11-05 20:52:04:000

Akcea Therapeutics (AKCA) Q3 2018 Earnings Conference Call November 05, 2018, 04:30 PM ET Executives Kathleen Gallagher - Vice President of Investor Relations and Corporate Communications Paula Soteropoulos - Chief Executive Officer Mike MacLean - Chief Financial Officer Sarah … read more...

Akcea Therapeutics beats by $0.07, beats on revenue

via: SeekingAlpha at 2018-11-05 17:11:47:000

Akcea Therapeutics (NASDAQ: AKCA ): Q3 GAAP EPS of -$0.73 beats by $0.07 . More news on: Akcea Therapeutics, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Akcea Q3 revenues up 94% but no Tegsedi sales; shares down 2% after hours

via: SeekingAlpha at 2018-11-05 16:21:36:000

Akcea Therapeutics (NASDAQ: AKCA )Q3 results ($M): Revenue: 19.2 (+93.9%) (license and R&D). No TEGSEDI sales yet. More news on: Akcea Therapeutics, Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more … read more...

Notable earnings after Monday's close

via: SeekingAlpha at 2018-11-04 17:35:05:000

ACHC , AEL , AKCA , ANDE , APLE , APTS , ATRO , ATUS , AVD , AWR , BE , BHF , BKD , BKH , BKNG , CAR , CBT , CDEV , COHU , CRZO , CTRE , CXW , DCO , DCP , DRH , DVAX , ELF , EVBG , FMC , FN , FNV , FRGI , FRPT , FTDR , HHC , IFF , INSY , IPAR , ITRI , … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-11-02 10:12:14:000

Noteworthy events during the week of November 4 - 10 for healthcare investors. More news on: Dare Bioscience, Inc., EyePoint Pharmaceuticals, Inc., Aduro Biotech, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-11-02 10:12:14:000

Noteworthy events during the week of November 4 - 10 for healthcare investors. More news on: Dare Bioscience, Inc., EyePoint Pharmaceuticals, Inc., Aduro Biotech, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-11-02 10:12:14:000

Noteworthy events during the week of November 4 - 10 for healthcare investors. More news on: Dare Bioscience, Inc., EyePoint Pharmaceuticals, Inc., Aduro Biotech, Healthcare stocks news, , Read more … read more...

FDA nod for Akcea's intersen fails to lift shares, down 16%

via: SeekingAlpha at 2018-10-08 15:43:40:000

Ionis Pharmaceuticals ( IONS -8.5% ) and affiliate Akcea Therapeutics ( AKCA -15.7% ) slump on increased volume following FDA approval for TEGSEDI (inotersen) for hATTR. Normally, a bullish event but investors appear concerned about its ability to compete with Alnylam Pharmaceuticals' ( … read more...

FDA nod for Akcea's intersen fails to lift shares, down 16%

via: SeekingAlpha at 2018-10-08 15:43:40:000

Ionis Pharmaceuticals ( IONS -8.5% ) and affiliate Akcea Therapeutics ( AKCA -15.7% ) slump on increased volume following FDA approval for TEGSEDI (inotersen) for hATTR. Normally, a bullish event but investors appear concerned about its ability to compete with Alnylam Pharmaceuticals' ( … read more...

FDA nod for Akcea's intersen fails to lift shares, down 16%

via: SeekingAlpha at 2018-10-08 15:43:40:000

Ionis Pharmaceuticals ( IONS -8.5% ) and affiliate Akcea Therapeutics ( AKCA -15.7% ) slump on increased volume following FDA approval for TEGSEDI (inotersen) for hATTR. Normally, a bullish event but investors appear concerned about its ability to compete with Alnylam Pharmaceuticals' ( … read more...

FDA OKs Akcea's inotersen for hATTR

via: SeekingAlpha at 2018-10-06 14:12:09:000

The FDA approves Akcea Therapeutics' (NASDAQ: AKCA ) TEGSEDI (inotersen) for the treatment of polyneuropathy in adults with hereditary transthyretin-mediated amyloidosis (hATTR). More news on: Akcea Therapeutics, Express Scripts, Inc., Ionis Pharmaceuticals, Inc., Healthcare stocks news,… read more...

FDA OKs Akcea's inotersen for hATTR

via: SeekingAlpha at 2018-10-06 14:12:09:000

The FDA approves Akcea Therapeutics' (NASDAQ: AKCA ) TEGSEDI (inotersen) for the treatment of polyneuropathy in adults with hereditary transthyretin-mediated amyloidosis (hATTR). More news on: Akcea Therapeutics, Express Scripts, Inc., Ionis Pharmaceuticals, Inc., Healthcare stocks news,… read more...

Akcea up 4% premmarket on positive mid-stage data on AKCEA-APO(a)-Lrx

via: SeekingAlpha at 2018-09-24 07:48:40:000

Ionis Pharmaceuticals (NASDAQ: IONS ) and affiliate and co-developer Akcea Therapeutics (NASDAQ: AKCA ) announce positive topline data from a Phase 2 clinical trial evaluating AKCEA-APO(a)-Lrx in patients with established cardiovascular disease (CVD) and elevated levels of lipoprotein(a) [… read more...

Akcea up 4% premmarket on positive mid-stage data on AKCEA-APO(a)-Lrx

via: SeekingAlpha at 2018-09-24 07:48:40:000

Ionis Pharmaceuticals (NASDAQ: IONS ) and affiliate and co-developer Akcea Therapeutics (NASDAQ: AKCA ) announce positive topline data from a Phase 2 clinical trial evaluating AKCEA-APO(a)-Lrx in patients with established cardiovascular disease (CVD) and elevated levels of lipoprotein(a) [… read more...

Akcea up 4% premmarket on positive mid-stage data on AKCEA-APO(a)-Lrx

via: SeekingAlpha at 2018-09-24 07:48:40:000

Ionis Pharmaceuticals (NASDAQ: IONS ) and affiliate and co-developer Akcea Therapeutics (NASDAQ: AKCA ) announce positive topline data from a Phase 2 clinical trial evaluating AKCEA-APO(a)-Lrx in patients with established cardiovascular disease (CVD) and elevated levels of lipoprotein(a) [… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-09-18 08:42:45:000

Akcea Therapeutics (NASDAQ: AKCA ) initiated with Buy rating and $45 (81% upside) price target at Needham. Shares up 4% premarket. More news on: Akcea Therapeutics, Surgery Partners, Inc., Universal Health Services Inc., Healthcare stocks news, Stocks on the move, , Read mo… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-09-18 08:42:45:000

Akcea Therapeutics (NASDAQ: AKCA ) initiated with Buy rating and $45 (81% upside) price target at Needham. Shares up 4% premarket. More news on: Akcea Therapeutics, Surgery Partners, Inc., Universal Health Services Inc., Healthcare stocks news, Stocks on the move, , Read mo… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-09-18 08:42:45:000

Akcea Therapeutics (NASDAQ: AKCA ) initiated with Buy rating and $45 (81% upside) price target at Needham. Shares up 4% premarket. More news on: Akcea Therapeutics, Surgery Partners, Inc., Universal Health Services Inc., Healthcare stocks news, Stocks on the move, , Read mo… read more...

Akcea Therapeutics: How To Profit On The Waylivra CRL?

via: SeekingAlpha at 2018-09-13 15:57:38:000

Always take the high road, it's far less crowded. - Charlie Munger Akcea Therapeutics (NASDAQ: AKCA ) is an RNA therapeutic innovator that has multiple powerful catalysts. The company recently gained an EU approval of its lead molecule (Tegsedi) only to witness a negative regulatory bina… read more...

Akcea Therapeutics: How To Profit On The Waylivra CRL?

via: SeekingAlpha at 2018-09-13 15:57:38:000

Always take the high road, it's far less crowded. - Charlie Munger Akcea Therapeutics (NASDAQ: AKCA ) is an RNA therapeutic innovator that has multiple powerful catalysts. The company recently gained an EU approval of its lead molecule (Tegsedi) only to witness a negative regulatory bina… read more...

Akcea Therapeutics: How To Profit On The Waylivra CRL?

via: SeekingAlpha at 2018-09-13 15:57:38:000

Always take the high road, it's far less crowded. - Charlie Munger Akcea Therapeutics (NASDAQ: AKCA ) is an RNA therapeutic innovator that has multiple powerful catalysts. The company recently gained an EU approval of its lead molecule (Tegsedi) only to witness a negative regulatory bina… read more...

Akcea to axe 10% of workforce

via: SeekingAlpha at 2018-09-06 16:38:53:000

Ionis Pharmaceuticals (NASDAQ: IONS ) affiliate Akcea Therapeutics (NASDAQ: AKCA ) discloses that it intends to cut 10% of its workforce as part of its reorganization plan following the FDA's rejection of its WAYLIVRA ( volanesorsen) marketing application. It expects to record a charge of … read more...

Akcea to axe 10% of workforce

via: SeekingAlpha at 2018-09-06 16:38:53:000

Ionis Pharmaceuticals (NASDAQ: IONS ) affiliate Akcea Therapeutics (NASDAQ: AKCA ) discloses that it intends to cut 10% of its workforce as part of its reorganization plan following the FDA's rejection of its WAYLIVRA ( volanesorsen) marketing application. It expects to record a charge of … read more...

Akcea to axe 10% of workforce

via: SeekingAlpha at 2018-09-06 16:38:53:000

Ionis Pharmaceuticals (NASDAQ: IONS ) affiliate Akcea Therapeutics (NASDAQ: AKCA ) discloses that it intends to cut 10% of its workforce as part of its reorganization plan following the FDA's rejection of its WAYLIVRA ( volanesorsen) marketing application. It expects to record a charge of … read more...

A Second Look At Inotersen's Approval Potential

via: SeekingAlpha at 2018-09-04 17:46:38:000

Editor's note: Seeking Alpha is proud to welcome Chris Stang as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Last week, Io… read more...

A Second Look At Inotersen's Approval Potential

via: SeekingAlpha at 2018-09-04 17:46:38:000

Editor's note: Seeking Alpha is proud to welcome Chris Stang as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Last week, Io… read more...

Stocks To Watch: Time To Talk Valuation

via: SeekingAlpha at 2018-09-01 08:28:12:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. The stock market could get a bit of a test as traders return back to their desks fo… read more...

Stocks To Watch: Time To Talk Valuation

via: SeekingAlpha at 2018-09-01 08:28:12:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. The stock market could get a bit of a test as traders return back to their desks fo… read more...

Stocks To Watch: Time To Talk Valuation

via: SeekingAlpha at 2018-09-01 08:28:12:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. The stock market could get a bit of a test as traders return back to their desks fo… read more...

Alnylam's patisiran OK'd in Europe for hATTR amyoidosis

via: SeekingAlpha at 2018-08-30 07:42:54:000

The European Commission approves Alnylam Pharmaceuticals' (NASDAQ: ALNY ) ONPATTRO (patisiran) for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adults with stager 1 or stage 2 polyneuropathy. More news on: Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals,… read more...

Alnylam's patisiran OK'd in Europe for hATTR amyoidosis

via: SeekingAlpha at 2018-08-30 07:42:54:000

The European Commission approves Alnylam Pharmaceuticals' (NASDAQ: ALNY ) ONPATTRO (patisiran) for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adults with stager 1 or stage 2 polyneuropathy. More news on: Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals,… read more...

Ionis Pharmaceuticals Receives CRL From FDA, But This Was Just A Minor Setback

via: SeekingAlpha at 2018-08-29 11:52:21:000

Ionis Pharmaceuticals ( IONS ) and Akcea Therapeutics ( AKCA ) announced that the FDA has rejected volanesorsen to treat patients with familial chylomicronemia syndrome ((FCS)). FCS is a disease that is associated with high levels of triglycerides . This FDA rejection was shocking, but … read more...

Midday Gainers / Losers (08/28/2018)

via: SeekingAlpha at 2018-08-28 12:45:53:000

Gainers: AFMD +220% . ATAI +43% . STAF +30% . ASFI +26% . BRKS +27% . VVPR +19% . DSW +18% . CVM +17% . BILI +16% . ABIL +15% . More news on: Affimed Therapeutics, ATA Inc., Staffing 360 Solutions, Inc., Stocks on the move, , Read more … read more...

Approval, Labeling, Pricing, And Competitor Data All Give Alnylam Pharmaceuticals A Wild Ride

via: SeekingAlpha at 2018-08-28 12:21:20:000

Its been an interesting period of time to be an Alnylam ( ALNY ) shareholder, as the company got its first FDA approval (Onpattro), but with a narrower label than hoped and a somewhat confusing price structure. On top of that, a key potential competitor that wasnt even seen a… read more...

Premarket Losers as of 9:05 am (8/28/2018)

via: SeekingAlpha at 2018-08-28 09:09:05:000

AKCA -28% after FDA rejection of volanesorsen. More news on: Akcea Therapeutics, Ionis Pharmaceuticals, Inc., India Globalization Capital, Inc, Stocks on the move, , Read more … read more...

Money flow stays positive in biotechs, XBI up 6% since last week

via: SeekingAlpha at 2018-08-27 11:39:49:000

Biotechs continue their modest rally. The SPDR S&P Biotech ETF ( XBI +1.9% ) is up albeit on below average. It has jumped 6% since last week. More news on: SPDR Biotech ETF, Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the … read more...

Sell-siders bullish on Pfizer tafamidis after release of positive data

via: SeekingAlpha at 2018-08-27 10:22:07:000

Sell-side analysts weigh in on Pfizer's ( PFE -1.9% ) Vyndaqel (tafamidis) after the company released late-stage data in patients with wild-type or variant (hereditary) transthyretin amyloid cardiomyopathy. More news on: Pfizer Inc., Alnylam Pharmaceuticals, Inc., Eidos Therapeutics, Hea… read more...

Stocks To Watch: Tesla Twist And Retail Rally

via: SeekingAlpha at 2018-08-25 07:07:25:000

Stocks To Watch: Tesla Twist And Retail Rocket Ride Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. The retail sector is on fire … read more...

Stocks To Watch: Tesla Twist And Retail Rally

via: SeekingAlpha at 2018-08-25 07:07:25:000

Stocks To Watch: Tesla Twist And Retail Rocket Ride Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. The retail sector is on fire … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-08-24 07:11:19:000

Noteworthy events for the week of August 26 - September 1 for healthcare investors. More news on: Amgen Inc., Pfizer Inc., Bausch Health Companies Inc., Healthcare stocks news, , Read more … read more...

Alnylam: Fully Priced, But A Future Star

via: SeekingAlpha at 2018-08-21 13:06:20:000

Investors often talk of getting in on the next big thing. But it is hard to know when a small thing will become big. I believe Alnylam ( ALNY ), which specializes in RNA based therapies, is part of a small number of biotechnology companies that will be part of a very big therapeutic space over… read more...

Alnylam: Fully Priced, But A Future Star

via: SeekingAlpha at 2018-08-21 13:06:20:000

Investors often talk of getting in on the next big thing. But it is hard to know when a small thing will become big. I believe Alnylam ( ALNY ), which specializes in RNA based therapies, is part of a small number of biotechnology companies that will be part of a very big therapeutic space over… read more...

Alnylam: Fully Priced, But A Future Star

via: SeekingAlpha at 2018-08-21 13:06:20:000

Investors often talk of getting in on the next big thing. But it is hard to know when a small thing will become big. I believe Alnylam ( ALNY ), which specializes in RNA based therapies, is part of a small number of biotechnology companies that will be part of a very big therapeutic space over… read more...

The Battle For Best-In-Class In ATTR Has Begun

via: SeekingAlpha at 2018-08-16 11:52:57:000

With Alnylam (NASDAQ: ALNY ) securing FDA approval for Onpattro on Friday, August 10 th , 2018, the battle for "best-in-class" in transthyretin amyloidosis (ATTR) has officially begun. This approval gives Alnylam the early lead. Other competitors in the clinic include Ionis (NASDAQ:… read more...

The Battle For Best-In-Class In ATTR Has Begun

via: SeekingAlpha at 2018-08-16 11:52:57:000

With Alnylam (NASDAQ: ALNY ) securing FDA approval for Onpattro on Friday, August 10 th , 2018, the battle for "best-in-class" in transthyretin amyloidosis (ATTR) has officially begun. This approval gives Alnylam the early lead. Other competitors in the clinic include Ionis (NASDAQ:… read more...

The Battle For Best-In-Class In ATTR Has Begun

via: SeekingAlpha at 2018-08-16 11:52:57:000

With Alnylam (NASDAQ: ALNY ) securing FDA approval for Onpattro on Friday, August 10 th , 2018, the battle for "best-in-class" in transthyretin amyloidosis (ATTR) has officially begun. This approval gives Alnylam the early lead. Other competitors in the clinic include Ionis (NASDAQ:… read more...

Akcea Therapeutics' (AKCA) CEO Paula Soteropoulos on Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-08-06 22:38:14:000

Akcea Therapeutics (AKCA) Q2 2018 Earnings Conference Call August 6, 2018 4:30 PM ET Executives Paula Soteropoulos Chief Executive Officer Kathleen Gallagher Vice President of Investor Relations and Corporate Communications Jeff Goldberg Chief Operating… read more...

Akcea Therapeutics' (AKCA) CEO Paula Soteropoulos on Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-08-06 22:38:14:000

Akcea Therapeutics (AKCA) Q2 2018 Earnings Conference Call August 6, 2018 4:30 PM ET Executives Paula Soteropoulos Chief Executive Officer Kathleen Gallagher Vice President of Investor Relations and Corporate Communications Jeff Goldberg Chief Operating… read more...

Akcea Therapeutics' (AKCA) CEO Paula Soteropoulos on Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-08-06 22:38:14:000

Akcea Therapeutics (AKCA) Q2 2018 Earnings Conference Call August 6, 2018 4:30 PM ET Executives Paula Soteropoulos Chief Executive Officer Kathleen Gallagher Vice President of Investor Relations and Corporate Communications Jeff Goldberg Chief Operating… read more...

Akcea Therapeutics beats by $0.39, beats on revenue

via: SeekingAlpha at 2018-08-06 16:42:55:000

Akcea Therapeutics (NASDAQ: AKCA ): Q2 EPS of -$0.85 beats by $0.39 . More news on: Akcea Therapeutics, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Alnylam About A Week Away From Its First Approval

via: SeekingAlpha at 2018-08-06 08:02:36:000

With an FDA PDUFA date about one week away for its lead drug patisiran (which Alnylam ( ALNY ) will market as Onpattro), the value in the companys second quarter earnings report was mostly in regard to its pipeline updates. Alynylam has ample cash to continue moving i… read more...

Notable earnings after Monday's close

via: SeekingAlpha at 2018-08-05 17:35:04:000

AEL , AKCA , AMRS , ANDV , ANDX , ANSS , APLE , ARNA , ATSG , AVD , AWR , BHF , BKD , BKH , BRKS , BWXT , CBT , CDEV , CMP , CPE , CRY , CRZO , CVCO , DCO , DPLO , DVAX , EDIT , ETSY , EVBG , FATE , FIVN , FRGI , FRPT , HHC , HTZ , ITRI , KMT , LGND , … read more...

PTC to commercialize two Akcea drugs in Latin America

via: SeekingAlpha at 2018-08-02 09:58:10:000

Akcea Therapeutics ( AKCA +1.3% ) inks an agreement with PTC Therapeutics ( PTCT -0.2% ) under which the latter will commercialize TEGSEDI (inotersen) and WAYLIVRA (volanesorsen) in Latin America. More news on: Akcea Therapeutics, PTC Therapeutics, Ionis Pharmaceuticals, Inc., Health… read more...

PTC to commercialize two Akcea drugs in Latin America

via: SeekingAlpha at 2018-08-02 09:58:10:000

Akcea Therapeutics ( AKCA +1.3% ) inks an agreement with PTC Therapeutics ( PTCT -0.2% ) under which the latter will commercialize TEGSEDI (inotersen) and WAYLIVRA (volanesorsen) in Latin America. More news on: Akcea Therapeutics, PTC Therapeutics, Ionis Pharmaceuticals, Inc., Health… read more...

PTC to commercialize two Akcea drugs in Latin America

via: SeekingAlpha at 2018-08-02 09:58:10:000

Akcea Therapeutics ( AKCA +1.3% ) inks an agreement with PTC Therapeutics ( PTCT -0.2% ) under which the latter will commercialize TEGSEDI (inotersen) and WAYLIVRA (volanesorsen) in Latin America. More news on: Akcea Therapeutics, PTC Therapeutics, Ionis Pharmaceuticals, Inc., Health… read more...

Akcea Therapeutics and PTC Therapeutics Collaborate to Commercialize Two Rare Disease Drugs in Latin America

via: PR Newswire at 2018-08-02 08:00:00:000

SOUTH PLAINFIELD, N.J. and CAMBRIDGE, Mass. , Aug. 2, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT), and Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced a collaboration under which PTC will commercialize t… read more...

Akcea Therapeutics and PTC Therapeutics Collaborate to Commercialize Two Rare Disease Drugs in Latin America

via: PR Newswire at 2018-08-02 08:00:00:000

SOUTH PLAINFIELD, N.J. and CAMBRIDGE, Mass. , Aug. 2, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT), and Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced a collaboration under which PTC will commercialize t… read more...

Akcea Therapeutics and PTC Therapeutics Collaborate to Commercialize Two Rare Disease Drugs in Latin America

via: PR Newswire at 2018-08-02 08:00:00:000

SOUTH PLAINFIELD, N.J. and CAMBRIDGE, Mass. , Aug. 2, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT), and Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced a collaboration under which PTC will commercialize t… read more...

Akcea Therapeutics: What The EU Tegsedi Approval Foretells

via: SeekingAlpha at 2018-07-20 05:59:19:000

Just as book value overstates true worth, it can understate true worth. This is where you get the greatest asset play. - Peter Lynch Akcea Therapeutics (NASDAQ: AKCA ) is a highly interesting grower featured in our Specialty Report on RNA-based medicines. The company is hitting a gro… read more...

Akcea Therapeutics: What The EU Tegsedi Approval Foretells

via: SeekingAlpha at 2018-07-20 05:59:19:000

Just as book value overstates true worth, it can understate true worth. This is where you get the greatest asset play. - Peter Lynch Akcea Therapeutics (NASDAQ: AKCA ) is a highly interesting grower featured in our Specialty Report on RNA-based medicines. The company is hitting a gro… read more...

Akcea Therapeutics: What The EU Tegsedi Approval Foretells

via: SeekingAlpha at 2018-07-20 05:59:19:000

Just as book value overstates true worth, it can understate true worth. This is where you get the greatest asset play. - Peter Lynch Akcea Therapeutics (NASDAQ: AKCA ) is a highly interesting grower featured in our Specialty Report on RNA-based medicines. The company is hitting a gro… read more...

Akcea Therapeutics: What The EU Tegsedi Approval Foretells

via: SeekingAlpha at 2018-07-20 05:59:19:000

Just as book value overstates true worth, it can understate true worth. This is where you get the greatest asset play. - Peter Lynch Akcea Therapeutics (NASDAQ: AKCA ) is a highly interesting grower featured in our Specialty Report on RNA-based medicines. The company is hitting a gro… read more...

Akcea Therapeutics: What The EU Tegsedi Approval Foretells

via: SeekingAlpha at 2018-07-20 05:59:19:000

Just as book value overstates true worth, it can understate true worth. This is where you get the greatest asset play. - Peter Lynch Akcea Therapeutics (NASDAQ: AKCA ) is a highly interesting grower featured in our Specialty Report on RNA-based medicines. The company is hitting a gro… read more...

Ionis Pharma's inotersen OK'd in Europe for hATTR

via: SeekingAlpha at 2018-07-11 07:58:08:000

As expected, the European Commission approves Ionis Pharmaceuticals (NASDAQ: IONS ) and affiliate Akcea Therapeutics' (NASDAQ: AKCA ) TEGSEDI (inotersen) for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR). More news … read more...

Ionis Pharma's inotersen OK'd in Europe for hATTR

via: SeekingAlpha at 2018-07-11 07:58:08:000

As expected, the European Commission approves Ionis Pharmaceuticals (NASDAQ: IONS ) and affiliate Akcea Therapeutics' (NASDAQ: AKCA ) TEGSEDI (inotersen) for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR). More news … read more...

Ionis Pharma's inotersen OK'd in Europe for hATTR

via: SeekingAlpha at 2018-07-11 07:58:08:000

As expected, the European Commission approves Ionis Pharmaceuticals (NASDAQ: IONS ) and affiliate Akcea Therapeutics' (NASDAQ: AKCA ) TEGSEDI (inotersen) for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR). More news … read more...

New England Journal of Medicine Publishes Results from Pivotal Study of TEGSEDI(TM) (inotersen) for the Treatment of Hereditary ATTR Amyloidosis

via: PR Newswire at 2018-07-05 07:00:00:000

CARLSBAD, Calif. , and CAMBRIDGE, Mass. , July 5, 2018 /PRNewswire/ --Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in antisense therapeutics, and its affiliate, Akcea Therapeutics (Nasdaq: AKCA), announced today that the final study results from NEURO-TTR, the pivotal stu… read more...

New England Journal of Medicine Publishes Results from Pivotal Study of TEGSEDI(TM) (inotersen) for the Treatment of Hereditary ATTR Amyloidosis

via: PR Newswire at 2018-07-05 07:00:00:000

CARLSBAD, Calif. , and CAMBRIDGE, Mass. , July 5, 2018 /PRNewswire/ --Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in antisense therapeutics, and its affiliate, Akcea Therapeutics (Nasdaq: AKCA), announced today that the final study results from NEURO-TTR, the pivotal stu… read more...

New England Journal of Medicine Publishes Results from Pivotal Study of TEGSEDI(TM) (inotersen) for the Treatment of Hereditary ATTR Amyloidosis

via: PR Newswire at 2018-07-05 07:00:00:000

CARLSBAD, Calif. , and CAMBRIDGE, Mass. , July 5, 2018 /PRNewswire/ --Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in antisense therapeutics, and its affiliate, Akcea Therapeutics (Nasdaq: AKCA), announced today that the final study results from NEURO-TTR, the pivotal stu… read more...

Specialty Report On RNA-Based Therapeutics: A Novel Approach To Stellar Medicinal Innovation

via: SeekingAlpha at 2018-06-29 02:52:13:000

A stock is not just a ticker symbol or an electronic blip; it is an ownership interest in an actual business, with an underlying value that does not depend on its share price. - Benjamin Graham Welcome to the Integrated BioSci Specialty Report on RNA-based therapeutic innovators. As a … read more...

Specialty Report On RNA-Based Therapeutics: A Novel Approach To Stellar Medicinal Innovation

via: SeekingAlpha at 2018-06-29 02:52:13:000

A stock is not just a ticker symbol or an electronic blip; it is an ownership interest in an actual business, with an underlying value that does not depend on its share price. - Benjamin Graham Welcome to the Integrated BioSci Specialty Report on RNA-based therapeutic innovators. As a … read more...

Specialty Report On RNA-Based Therapeutics: A Novel Approach To Stellar Medicinal Innovation

via: SeekingAlpha at 2018-06-29 02:52:13:000

A stock is not just a ticker symbol or an electronic blip; it is an ownership interest in an actual business, with an underlying value that does not depend on its share price. - Benjamin Graham Welcome to the Integrated BioSci Specialty Report on RNA-based therapeutic innovators. As a … read more...

Specialty Report On RNA-Based Therapeutics: A Novel Approach To Stellar Medicinal Innovation

via: SeekingAlpha at 2018-06-29 02:52:13:000

A stock is not just a ticker symbol or an electronic blip; it is an ownership interest in an actual business, with an underlying value that does not depend on its share price. - Benjamin Graham Welcome to the Integrated BioSci Specialty Report on RNA-based therapeutic innovators. As a … read more...

Specialty Report On RNA-Based Therapeutics: A Novel Approach To Stellar Medicinal Innovation

via: SeekingAlpha at 2018-06-29 02:52:13:000

A stock is not just a ticker symbol or an electronic blip; it is an ownership interest in an actual business, with an underlying value that does not depend on its share price. - Benjamin Graham Welcome to the Integrated BioSci Specialty Report on RNA-based therapeutic innovators. As a … read more...

Akcea And Ionis: What The Latest Regulatory Catalyst For Inotersen Foretells

via: SeekingAlpha at 2018-06-08 03:06:02:000

The best way to measure your investing success is not by whether you're beating the market but by whether you've put in place a financial plan and a behavioral discipline that are likely to get you where you want to go. - Benjamin Graham We have presented many stellar therapeutic… read more...

Akcea And Ionis: What The Latest Regulatory Catalyst For Inotersen Foretells

via: SeekingAlpha at 2018-06-08 03:06:02:000

The best way to measure your investing success is not by whether you're beating the market but by whether you've put in place a financial plan and a behavioral discipline that are likely to get you where you want to go. - Benjamin Graham We have presented many stellar therapeutic… read more...

Akcea And Ionis: What The Latest Regulatory Catalyst For Inotersen Foretells

via: SeekingAlpha at 2018-06-08 03:06:02:000

The best way to measure your investing success is not by whether you're beating the market but by whether you've put in place a financial plan and a behavioral discipline that are likely to get you where you want to go. - Benjamin Graham We have presented many stellar therapeutic… read more...

Akcea And Ionis: What The Latest Regulatory Catalyst For Inotersen Foretells

via: SeekingAlpha at 2018-06-08 03:06:02:000

The best way to measure your investing success is not by whether you're beating the market but by whether you've put in place a financial plan and a behavioral discipline that are likely to get you where you want to go. - Benjamin Graham We have presented many stellar therapeutic… read more...

Akcea And Ionis: What The Latest Regulatory Catalyst For Inotersen Foretells

via: SeekingAlpha at 2018-06-08 03:06:02:000

The best way to measure your investing success is not by whether you're beating the market but by whether you've put in place a financial plan and a behavioral discipline that are likely to get you where you want to go. - Benjamin Graham We have presented many stellar therapeutic… read more...

Core Biotech Buys #18: Thoughts On ASCO And The End Of Core Biotech

via: SeekingAlpha at 2018-06-07 16:03:56:000

Welcome to the eighteenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the size… read more...

Eidos Therapeutics files for initial public offering

via: SeekingAlpha at 2018-05-25 17:13:24:000

Eidos Therapeutics has filed for an initial public offering with an initial registration for $115M. More news on: Pfizer Inc., Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Healthcare stocks news, IPOs, Read more … read more...

Eidos Therapeutics files for initial public offering

via: SeekingAlpha at 2018-05-25 17:13:24:000

Eidos Therapeutics has filed for an initial public offering with an initial registration for $115M. More news on: Pfizer Inc., Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Healthcare stocks news, IPOs, Read more … read more...

Eidos Therapeutics files for initial public offering

via: SeekingAlpha at 2018-05-25 17:13:24:000

Eidos Therapeutics has filed for an initial public offering with an initial registration for $115M. More news on: Pfizer Inc., Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Healthcare stocks news, IPOs, Read more … read more...

Eidos Therapeutics files for initial public offering

via: SeekingAlpha at 2018-05-25 17:13:24:000

Eidos Therapeutics has filed for an initial public offering with an initial registration for $115M. More news on: Pfizer Inc., Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Healthcare stocks news, IPOs, Read more … read more...

Eidos Therapeutics files for initial public offering

via: SeekingAlpha at 2018-05-25 17:13:24:000

Eidos Therapeutics has filed for an initial public offering with an initial registration for $115M. More news on: Pfizer Inc., Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Healthcare stocks news, IPOs, Read more … read more...

Eidos Therapeutics files for initial public offering

via: SeekingAlpha at 2018-05-25 17:13:24:000

Eidos Therapeutics has filed for an initial public offering with an initial registration for $115M. More news on: Pfizer Inc., Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Healthcare stocks news, IPOs, Read more … read more...

Ionis And Akcea Obtain Positive Recommendation From Panel, Can They Go All The Way?

via: SeekingAlpha at 2018-05-14 02:44:26:000

Recently, it was announced that Ionis Pharmaceuticals ( IONS ) and Akcea Therapeutics ( AKCA ) received a positive vote from the FDA advisory panel. This bodes well for FDA approval of volanesorsen, because the panel vote came in better than expected. The FDA doesn't have to listen to the … read more...

Ionis And Akcea Obtain Positive Recommendation From Panel, Can They Go All The Way?

via: SeekingAlpha at 2018-05-14 02:44:26:000

Recently, it was announced that Ionis Pharmaceuticals ( IONS ) and Akcea Therapeutics ( AKCA ) received a positive vote from the FDA advisory panel. This bodes well for FDA approval of volanesorsen, because the panel vote came in better than expected. The FDA doesn't have to listen to the … read more...

Your Daily Pharma Scoop: Our Watchlist Pick ARMO Acquired, Ziopharma Low Cash, Coherus PDUFA Date

via: SeekingAlpha at 2018-05-11 10:00:00:000

Analysis focus: ARMO Eli Lilly (NYSE: LLY ) has agreed to acquire ARMO BioSciences for $1.6bn ($50/share) in cash. This is almost a 40% premium to ARMOs previous closing price of $29.82. It is currently trading at $49.80. The transaction will close this quarter, helping Lilly bol… read more...

Your Daily Pharma Scoop: Our Watchlist Pick ARMO Acquired, Ziopharma Low Cash, Coherus PDUFA Date

via: SeekingAlpha at 2018-05-11 10:00:00:000

Analysis focus: ARMO Eli Lilly (NYSE: LLY ) has agreed to acquire ARMO BioSciences for $1.6bn ($50/share) in cash. This is almost a 40% premium to ARMOs previous closing price of $29.82. It is currently trading at $49.80. The transaction will close this quarter, helping Lilly bol… read more...

Ionis and Akcea up premarket after Ad Com vote

via: SeekingAlpha at 2018-05-11 08:08:12:000

Ionis Pharmaceuticals (NASDAQ: IONS ) and affiliate Akcea Therapeutics (NASDAQ: AKCA ) are up 3% and 16% , respectively, in light premarket trade after an FDA Ad Com voted 12 - 8 backing volanesoren, branded as WAYLIVRA, for familial chylomicronemia syndrome. More news on… read more...

Ionis and Akcea up premarket after Ad Com vote

via: SeekingAlpha at 2018-05-11 08:08:12:000

Ionis Pharmaceuticals (NASDAQ: IONS ) and affiliate Akcea Therapeutics (NASDAQ: AKCA ) are up 3% and 16% , respectively, in light premarket trade after an FDA Ad Com voted 12 - 8 backing volanesoren, branded as WAYLIVRA, for familial chylomicronemia syndrome. More news on… read more...

FDA Ad Com renders split vote on Akcea's volanesoren

via: SeekingAlpha at 2018-05-10 17:02:32:000

The FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 12 - 8 that Akcea Therapeutics' (NASDAQ: AKCA ) volanesoren should be approved in the U.S. More news on: Akcea Therapeutics, Ionis Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

FDA Ad Com renders split vote on Akcea's volanesoren

via: SeekingAlpha at 2018-05-10 17:02:32:000

The FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 12 - 8 that Akcea Therapeutics' (NASDAQ: AKCA ) volanesoren should be approved in the U.S. More news on: Akcea Therapeutics, Ionis Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Akcea Therapeutics, Inc. - AKCA

via: PR Newswire at 2018-05-10 14:38:00:000

NEW YORK , May 10, 2018 /PRNewswire/ --Pomerantz LLP is investigating claims on behalf of investors of Akcea Therapeutics, Inc.("Akcea" or the "Company") (NASDAQ:AKCA). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com … read more...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Akcea Therapeutics, Inc. - AKCA

via: PR Newswire at 2018-05-10 14:38:00:000

NEW YORK , May 10, 2018 /PRNewswire/ --Pomerantz LLP is investigating claims on behalf of investors of Akcea Therapeutics, Inc.("Akcea" or the "Company") (NASDAQ:AKCA). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com … read more...

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Akcea Therapeutics, Inc. (AKCA)

via: PR Newswire at 2018-05-10 10:57:00:000

NEW YORK , May 10, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akcea Therapeutics, Inc.("Akcea" or the "Company") (NASDAQ:AKCA). Such investors are encouraged to obtain a… read more...

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Akcea Therapeutics, Inc. (AKCA)

via: PR Newswire at 2018-05-10 10:57:00:000

NEW YORK , May 10, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akcea Therapeutics, Inc.("Akcea" or the "Company") (NASDAQ:AKCA). Such investors are encouraged to obtain a… read more...

Biotech Analysis Central Pharma News: Takeda's Acquisition Win, Ionis And Akcea Tumble, Alnylam's Advance In CNS

via: SeekingAlpha at 2018-05-09 01:40:03:000

Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Takeda Acquires Shire For $62 Billion News: It was announced recently that Takeda ( TKPYY ) would pay $62 billion in total to acquire rare disea… read more...

Biotech Analysis Central Pharma News: Takeda's Acquisition Win, Ionis And Akcea Tumble, Alnylam's Advance In CNS

via: SeekingAlpha at 2018-05-09 01:40:03:000

Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Takeda Acquires Shire For $62 Billion News: It was announced recently that Takeda ( TKPYY ) would pay $62 billion in total to acquire rare disea… read more...

Premarket Losers as of 9:05 am (5/8/2018)

via: SeekingAlpha at 2018-05-08 09:19:20:000

ARLZ -26% on terminating U.S. operations. More news on: Aralez Pharmaceuticals Inc., Nevro, Nobilis Health Corp., Stocks on the move, , Read more … read more...

Premarket Losers as of 9:05 am (5/8/2018)

via: SeekingAlpha at 2018-05-08 09:19:20:000

ARLZ -26% on terminating U.S. operations. More news on: Aralez Pharmaceuticals Inc., Nevro, Nobilis Health Corp., Stocks on the move, , Read more … read more...

FDA Ad Com Thursday for Akcea's volanesoren

via: SeekingAlpha at 2018-05-08 08:18:54:000

The FDA's Endocrinologic and Metabolic Drugs Advisory Committee will meet Thursday, May 10, to discuss Akcea Therapeutics' (NASDAQ: AKCA ) marketing application seeking approval for volanesoren as an adjunct to diet for the treatment of patients with familial chylomicronemia syndrome. More… read more...

FDA Ad Com Thursday for Akcea's volanesoren

via: SeekingAlpha at 2018-05-08 08:18:54:000

The FDA's Endocrinologic and Metabolic Drugs Advisory Committee will meet Thursday, May 10, to discuss Akcea Therapeutics' (NASDAQ: AKCA ) marketing application seeking approval for volanesoren as an adjunct to diet for the treatment of patients with familial chylomicronemia syndrome. More… read more...

Biotech Forum: The Week Ahead

via: SeekingAlpha at 2018-05-07 09:52:19:000

I do not care so much what I am to others as I care what I am to myself . Michel de Montaigne The market staged a large and late rally Friday to end the week on an up note. However, most indices ended flat or slightly down on the week. Apple (AAPL) hit an all-time and … read more...

Biotech Forum: The Week Ahead

via: SeekingAlpha at 2018-05-07 09:52:19:000

I do not care so much what I am to others as I care what I am to myself . Michel de Montaigne The market staged a large and late rally Friday to end the week on an up note. However, most indices ended flat or slightly down on the week. Apple (AAPL) hit an all-time and … read more...

FDA Ad Com May 10 for Akcea's volanesorsen

via: SeekingAlpha at 2018-02-15 09:18:35:000

The FDA's Endocrinologic and Metabolic Drugs Advisory Committee will meet on May 10 to discuss Ionis Pharmaceuticals (NASDAQ: IONS ) affiliate Akcea Therapeutics' (NASDAQ: AKCA ) marketing application seeking approval for Orphan Drug-tagged volanesorsen for the treatment of a rare inherite… read more...

FDA Ad Com May 10 for Akcea's volanesorsen

via: SeekingAlpha at 2018-02-15 09:18:35:000

The FDA's Endocrinologic and Metabolic Drugs Advisory Committee will meet on May 10 to discuss Ionis Pharmaceuticals (NASDAQ: IONS ) affiliate Akcea Therapeutics' (NASDAQ: AKCA ) marketing application seeking approval for Orphan Drug-tagged volanesorsen for the treatment of a rare inherite… read more...

FDA Ad Com May 10 for Akcea's volanesorsen

via: SeekingAlpha at 2018-02-15 09:18:35:000

The FDA's Endocrinologic and Metabolic Drugs Advisory Committee will meet on May 10 to discuss Ionis Pharmaceuticals (NASDAQ: IONS ) affiliate Akcea Therapeutics' (NASDAQ: AKCA ) marketing application seeking approval for Orphan Drug-tagged volanesorsen for the treatment of a rare inherite… read more...

FDA Ad Com May 10 for Akcea's volanesorsen

via: SeekingAlpha at 2018-02-15 09:18:35:000

The FDA's Endocrinologic and Metabolic Drugs Advisory Committee will meet on May 10 to discuss Ionis Pharmaceuticals (NASDAQ: IONS ) affiliate Akcea Therapeutics' (NASDAQ: AKCA ) marketing application seeking approval for Orphan Drug-tagged volanesorsen for the treatment of a rare inherite… read more...

FDA Ad Com May 10 for Akcea's volanesorsen

via: SeekingAlpha at 2018-02-15 09:18:35:000

The FDA's Endocrinologic and Metabolic Drugs Advisory Committee will meet on May 10 to discuss Ionis Pharmaceuticals (NASDAQ: IONS ) affiliate Akcea Therapeutics' (NASDAQ: AKCA ) marketing application seeking approval for Orphan Drug-tagged volanesorsen for the treatment of a rare inherite… read more...

FDA Ad Com May 10 for Akcea's volanesorsen

via: SeekingAlpha at 2018-02-15 09:18:35:000

The FDA's Endocrinologic and Metabolic Drugs Advisory Committee will meet on May 10 to discuss Ionis Pharmaceuticals (NASDAQ: IONS ) affiliate Akcea Therapeutics' (NASDAQ: AKCA ) marketing application seeking approval for Orphan Drug-tagged volanesorsen for the treatment of a rare inherite… read more...

FDA Ad Com May 10 for Akcea's volanesorsen

via: SeekingAlpha at 2018-02-15 09:18:35:000

The FDA's Endocrinologic and Metabolic Drugs Advisory Committee will meet on May 10 to discuss Ionis Pharmaceuticals (NASDAQ: IONS ) affiliate Akcea Therapeutics' (NASDAQ: AKCA ) marketing application seeking approval for Orphan Drug-tagged volanesorsen for the treatment of a rare inherite… read more...

FDA Ad Com May 10 for Akcea's volanesorsen

via: SeekingAlpha at 2018-02-15 09:18:35:000

The FDA's Endocrinologic and Metabolic Drugs Advisory Committee will meet on May 10 to discuss Ionis Pharmaceuticals (NASDAQ: IONS ) affiliate Akcea Therapeutics' (NASDAQ: AKCA ) marketing application seeking approval for Orphan Drug-tagged volanesorsen for the treatment of a rare inherite… read more...

FDA Ad Com May 10 for Akcea's volanesorsen

via: SeekingAlpha at 2018-02-15 09:18:35:000

The FDA's Endocrinologic and Metabolic Drugs Advisory Committee will meet on May 10 to discuss Ionis Pharmaceuticals (NASDAQ: IONS ) affiliate Akcea Therapeutics' (NASDAQ: AKCA ) marketing application seeking approval for Orphan Drug-tagged volanesorsen for the treatment of a rare inherite… read more...

FDA Ad Com May 10 for Akcea's volanesorsen

via: SeekingAlpha at 2018-02-15 09:18:35:000

The FDA's Endocrinologic and Metabolic Drugs Advisory Committee will meet on May 10 to discuss Ionis Pharmaceuticals (NASDAQ: IONS ) affiliate Akcea Therapeutics' (NASDAQ: AKCA ) marketing application seeking approval for Orphan Drug-tagged volanesorsen for the treatment of a rare inherite… read more...

FDA Ad Com May 10 for Akcea's volanesorsen

via: SeekingAlpha at 2018-02-15 09:18:35:000

The FDA's Endocrinologic and Metabolic Drugs Advisory Committee will meet on May 10 to discuss Ionis Pharmaceuticals (NASDAQ: IONS ) affiliate Akcea Therapeutics' (NASDAQ: AKCA ) marketing application seeking approval for Orphan Drug-tagged volanesorsen for the treatment of a rare inherite… read more...

FDA Ad Com May 10 for Akcea's volanesorsen

via: SeekingAlpha at 2018-02-15 09:18:35:000

The FDA's Endocrinologic and Metabolic Drugs Advisory Committee will meet on May 10 to discuss Ionis Pharmaceuticals (NASDAQ: IONS ) affiliate Akcea Therapeutics' (NASDAQ: AKCA ) marketing application seeking approval for Orphan Drug-tagged volanesorsen for the treatment of a rare inherite… read more...

FDA Ad Com May 10 for Akcea's volanesorsen

via: SeekingAlpha at 2018-02-15 09:18:35:000

The FDA's Endocrinologic and Metabolic Drugs Advisory Committee will meet on May 10 to discuss Ionis Pharmaceuticals (NASDAQ: IONS ) affiliate Akcea Therapeutics' (NASDAQ: AKCA ) marketing application seeking approval for Orphan Drug-tagged volanesorsen for the treatment of a rare inherite… read more...

FDA Ad Com May 10 for Akcea's volanesorsen

via: SeekingAlpha at 2018-02-15 09:18:35:000

The FDA's Endocrinologic and Metabolic Drugs Advisory Committee will meet on May 10 to discuss Ionis Pharmaceuticals (NASDAQ: IONS ) affiliate Akcea Therapeutics' (NASDAQ: AKCA ) marketing application seeking approval for Orphan Drug-tagged volanesorsen for the treatment of a rare inherite… read more...

Ionis: Good Value With Non-Binary Upside

via: SeekingAlpha at 2018-02-02 11:59:15:000

Antisense Technology Ionis ( IONS ) is considered to be one of the leaders in discovering and developing RNA-targeted therapeutics. Ionis has created a broadly applicable drug discovery antisense technology platform to develop a large, diverse, and advanced pipeline of potentially first-in… read more...

Ionis: Good Value With Non-Binary Upside

via: SeekingAlpha at 2018-02-02 11:59:15:000

Antisense Technology Ionis ( IONS ) is considered to be one of the leaders in discovering and developing RNA-targeted therapeutics. Ionis has created a broadly applicable drug discovery antisense technology platform to develop a large, diverse, and advanced pipeline of potentially first-in… read more...

Ionis: Good Value With Non-Binary Upside

via: SeekingAlpha at 2018-02-02 11:59:15:000

Antisense Technology Ionis ( IONS ) is considered to be one of the leaders in discovering and developing RNA-targeted therapeutics. Ionis has created a broadly applicable drug discovery antisense technology platform to develop a large, diverse, and advanced pipeline of potentially first-in… read more...

Ionis: Good Value With Non-Binary Upside

via: SeekingAlpha at 2018-02-02 11:59:15:000

Antisense Technology Ionis ( IONS ) is considered to be one of the leaders in discovering and developing RNA-targeted therapeutics. Ionis has created a broadly applicable drug discovery antisense technology platform to develop a large, diverse, and advanced pipeline of potentially first-in… read more...

Ionis: Good Value With Non-Binary Upside

via: SeekingAlpha at 2018-02-02 11:59:15:000

Antisense Technology Ionis ( IONS ) is considered to be one of the leaders in discovering and developing RNA-targeted therapeutics. Ionis has created a broadly applicable drug discovery antisense technology platform to develop a large, diverse, and advanced pipeline of potentially first-in… read more...

Midday Gainers / Losers (1/29/2018)

via: SeekingAlpha at 2018-01-29 12:45:04:000

Gainers: IMMR +47% . KS +30% . OSN +28% . DPS +23% . MATX +23% . CVO +22% . BLDP +18% . AKCA +15% . PTGX +14% . KDMN +13% . More news on: Immersion Corporation, KapStone Paper and Packaging Corporation, Ossen Innovation Co., Ltd., Stocks on the move, Re… read more...

Midday Gainers / Losers (1/29/2018)

via: SeekingAlpha at 2018-01-29 12:45:04:000

Gainers: IMMR +47% . KS +30% . OSN +28% . DPS +23% . MATX +23% . CVO +22% . BLDP +18% . AKCA +15% . PTGX +14% . KDMN +13% . More news on: Immersion Corporation, KapStone Paper and Packaging Corporation, Ossen Innovation Co., Ltd., Stocks on the move, Re… read more...

Midday Gainers / Losers (1/29/2018)

via: SeekingAlpha at 2018-01-29 12:45:04:000

Gainers: IMMR +47% . KS +30% . OSN +28% . DPS +23% . MATX +23% . CVO +22% . BLDP +18% . AKCA +15% . PTGX +14% . KDMN +13% . More news on: Immersion Corporation, KapStone Paper and Packaging Corporation, Ossen Innovation Co., Ltd., Stocks on the move, Re… read more...

Stocks to watch next week

via: SeekingAlpha at 2018-01-06 09:10:16:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. More news on: Apple Inc., Amazon.com, Inc., Intel Corporation, Tech stocks news, … read more...

Stocks to watch next week

via: SeekingAlpha at 2018-01-06 09:10:16:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. More news on: Apple Inc., Amazon.com, Inc., Intel Corporation, Tech stocks news, … read more...

Stocks to watch next week

via: SeekingAlpha at 2018-01-06 09:10:16:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. More news on: Apple Inc., Amazon.com, Inc., Intel Corporation, Tech stocks news, … read more...

Stocks to watch next week

via: SeekingAlpha at 2018-01-06 09:10:16:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. More news on: Apple Inc., Amazon.com, Inc., Intel Corporation, Tech stocks news, … read more...

Stocks to watch next week

via: SeekingAlpha at 2018-01-06 09:10:16:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. More news on: Apple Inc., Amazon.com, Inc., Intel Corporation, Tech stocks news, … read more...

Akcea Therapeutics launches mid-stage study of AKCEA-APOCIII-Lrx in patients with elevated triglycerides and CV disease

via: SeekingAlpha at 2018-01-05 16:28:39:000

Ionis Pharmaceuticals affiliate Akcea Therapeutics (NASDAQ: AKCA ) initiates a Phase 2b clinical trial assessing AKCEA-APOCIII-Lrx in patients with high triglycerides (hypertriglyceridemia) and established cardiovascular (CV) disease. The study will evaluate different doses and dosing freq… read more...

Akcea Therapeutics launches mid-stage study of AKCEA-APOCIII-Lrx in patients with elevated triglycerides and CV disease

via: SeekingAlpha at 2018-01-05 16:28:39:000

Ionis Pharmaceuticals affiliate Akcea Therapeutics (NASDAQ: AKCA ) initiates a Phase 2b clinical trial assessing AKCEA-APOCIII-Lrx in patients with high triglycerides (hypertriglyceridemia) and established cardiovascular (CV) disease. The study will evaluate different doses and dosing freq… read more...

Akcea Therapeutics launches mid-stage study of AKCEA-APOCIII-Lrx in patients with elevated triglycerides and CV disease

via: SeekingAlpha at 2018-01-05 16:28:39:000

Ionis Pharmaceuticals affiliate Akcea Therapeutics (NASDAQ: AKCA ) initiates a Phase 2b clinical trial assessing AKCEA-APOCIII-Lrx in patients with high triglycerides (hypertriglyceridemia) and established cardiovascular (CV) disease. The study will evaluate different doses and dosing freq… read more...

Akcea Therapeutics launches mid-stage study of AKCEA-APOCIII-Lrx in patients with elevated triglycerides and CV disease

via: SeekingAlpha at 2018-01-05 16:28:39:000

Ionis Pharmaceuticals affiliate Akcea Therapeutics (NASDAQ: AKCA ) initiates a Phase 2b clinical trial assessing AKCEA-APOCIII-Lrx in patients with high triglycerides (hypertriglyceridemia) and established cardiovascular (CV) disease. The study will evaluate different doses and dosing freq… read more...

Akcea Therapeutics launches mid-stage study of AKCEA-APOCIII-Lrx in patients with elevated triglycerides and CV disease

via: SeekingAlpha at 2018-01-05 16:28:39:000

Ionis Pharmaceuticals affiliate Akcea Therapeutics (NASDAQ: AKCA ) initiates a Phase 2b clinical trial assessing AKCEA-APOCIII-Lrx in patients with high triglycerides (hypertriglyceridemia) and established cardiovascular (CV) disease. The study will evaluate different doses and dosing freq… read more...

Akcea launches mid-stage study of LICA candidate in patients with diabetes, high triglycerides and fatty liver disease; shares up 3%

via: SeekingAlpha at 2017-12-14 09:51:17:000

Ionis Pharmaceuticals ( IONS -1.4% ) affiliate Akcea Therapeutics ( AKCA +2.6% ) launches a Phase 2 clinical trial assessing AKCEA-ANGPTL3-Lrx in patients with diabetes, hypertriglyceridemia (high blood triglycerides) and nonalcoholic fatty liver disease (NAFLD). More news on: Ioni… read more...

Akcea launches mid-stage study of LICA candidate in patients with diabetes, high triglycerides and fatty liver disease; shares up 3%

via: SeekingAlpha at 2017-12-14 09:51:17:000

Ionis Pharmaceuticals ( IONS -1.4% ) affiliate Akcea Therapeutics ( AKCA +2.6% ) launches a Phase 2 clinical trial assessing AKCEA-ANGPTL3-Lrx in patients with diabetes, hypertriglyceridemia (high blood triglycerides) and nonalcoholic fatty liver disease (NAFLD). More news on: Ioni… read more...

Akcea launches mid-stage study of LICA candidate in patients with diabetes, high triglycerides and fatty liver disease; shares up 3%

via: SeekingAlpha at 2017-12-14 09:51:17:000

Ionis Pharmaceuticals ( IONS -1.4% ) affiliate Akcea Therapeutics ( AKCA +2.6% ) launches a Phase 2 clinical trial assessing AKCEA-ANGPTL3-Lrx in patients with diabetes, hypertriglyceridemia (high blood triglycerides) and nonalcoholic fatty liver disease (NAFLD). More news on: Ioni… read more...

Akcea launches mid-stage study of LICA candidate in patients with diabetes, high triglycerides and fatty liver disease; shares up 3%

via: SeekingAlpha at 2017-12-14 09:51:17:000

Ionis Pharmaceuticals ( IONS -1.4% ) affiliate Akcea Therapeutics ( AKCA +2.6% ) launches a Phase 2 clinical trial assessing AKCEA-ANGPTL3-Lrx in patients with diabetes, hypertriglyceridemia (high blood triglycerides) and nonalcoholic fatty liver disease (NAFLD). More news on: Ioni… read more...

Akcea launches mid-stage study of LICA candidate in patients with diabetes, high triglycerides and fatty liver disease; shares up 3%

via: SeekingAlpha at 2017-12-14 09:51:17:000

Ionis Pharmaceuticals ( IONS -1.4% ) affiliate Akcea Therapeutics ( AKCA +2.6% ) launches a Phase 2 clinical trial assessing AKCEA-ANGPTL3-Lrx in patients with diabetes, hypertriglyceridemia (high blood triglycerides) and nonalcoholic fatty liver disease (NAFLD). More news on: Ioni… read more...

Nasdaq Biotech Index: 54 to be added, 15 removed

via: SeekingAlpha at 2017-12-11 07:45:08:000

Changes will become effective prior to the open next Monday. ETF: IBB More news on: iShares Nasdaq Biotechnology ETF, Arbutus Biopharma Corp, Aclaris Therapeutics, Healthcare stocks news, News on ETFs, Read more … read more...

Nasdaq Biotech Index: 54 to be added, 15 removed

via: SeekingAlpha at 2017-12-11 07:45:08:000

Changes will become effective prior to the open next Monday. ETF: IBB More news on: iShares Nasdaq Biotechnology ETF, Arbutus Biopharma Corp, Aclaris Therapeutics, Healthcare stocks news, News on ETFs, Read more … read more...

Nasdaq Biotech Index: 54 to be added, 15 removed

via: SeekingAlpha at 2017-12-11 07:45:08:000

Changes will become effective prior to the open next Monday. ETF: IBB More news on: iShares Nasdaq Biotechnology ETF, Arbutus Biopharma Corp, Aclaris Therapeutics, Healthcare stocks news, News on ETFs, Read more … read more...

Nasdaq Biotech Index: 54 to be added, 15 removed

via: SeekingAlpha at 2017-12-11 07:45:08:000

Changes will become effective prior to the open next Monday. ETF: IBB More news on: iShares Nasdaq Biotechnology ETF, Arbutus Biopharma Corp, Aclaris Therapeutics, Healthcare stocks news, News on ETFs, Read more … read more...

Nasdaq Biotech Index: 54 to be added, 15 removed

via: SeekingAlpha at 2017-12-11 07:45:08:000

Changes will become effective prior to the open next Monday. ETF: IBB More news on: iShares Nasdaq Biotechnology ETF, Arbutus Biopharma Corp, Aclaris Therapeutics, Healthcare stocks news, News on ETFs, Read more … read more...

After Hours Gainers / Losers

via: SeekingAlpha at 2017-11-24 15:04:46:000

Top gainers: CYTK +3.9% . PAA +3.7% . SOGO +1.7% . REDU +1.2% . ACHN +0.9% . More news on: Cytokinetics, Incorporated, Plains All American Pipeline, L.P., Sogou, Stocks on the move, Read more … read more...

After Hours Gainers / Losers

via: SeekingAlpha at 2017-11-24 15:04:46:000

Top gainers: CYTK +3.9% . PAA +3.7% . SOGO +1.7% . REDU +1.2% . ACHN +0.9% . More news on: Cytokinetics, Incorporated, Plains All American Pipeline, L.P., Sogou, Stocks on the move, Read more … read more...

After Hours Gainers / Losers

via: SeekingAlpha at 2017-11-24 15:04:46:000

Top gainers: CYTK +3.9% . PAA +3.7% . SOGO +1.7% . REDU +1.2% . ACHN +0.9% . More news on: Cytokinetics, Incorporated, Plains All American Pipeline, L.P., Sogou, Stocks on the move, Read more … read more...

After Hours Gainers / Losers

via: SeekingAlpha at 2017-11-24 15:04:46:000

Top gainers: CYTK +3.9% . PAA +3.7% . SOGO +1.7% . REDU +1.2% . ACHN +0.9% . More news on: Cytokinetics, Incorporated, Plains All American Pipeline, L.P., Sogou, Stocks on the move, Read more … read more...

After Hours Gainers / Losers

via: SeekingAlpha at 2017-11-24 15:04:46:000

Top gainers: CYTK +3.9% . PAA +3.7% . SOGO +1.7% . REDU +1.2% . ACHN +0.9% . More news on: Cytokinetics, Incorporated, Plains All American Pipeline, L.P., Sogou, Stocks on the move, Read more … read more...

Akcea Therapeutics (AKCA) Presents At Stifel 2017 Healthcare Conference - Slideshow

via: SeekingAlpha at 2017-11-16 14:06:20:000

The following slide deck was published by Akcea Therapeutics in conjunction with this Read more … read more...

Akcea Therapeutics (AKCA) Presents At Stifel 2017 Healthcare Conference - Slideshow

via: SeekingAlpha at 2017-11-16 14:06:20:000

The following slide deck was published by Akcea Therapeutics in conjunction with this Read more … read more...

Akcea Therapeutics (AKCA) Presents At Stifel 2017 Healthcare Conference - Slideshow

via: SeekingAlpha at 2017-11-16 14:06:20:000

The following slide deck was published by Akcea Therapeutics in conjunction with this Read more … read more...

Akcea Therapeutics (AKCA) Presents At Stifel 2017 Healthcare Conference - Slideshow

via: SeekingAlpha at 2017-11-16 14:06:20:000

The following slide deck was published by Akcea Therapeutics in conjunction with this Read more … read more...

Akcea Therapeutics (AKCA) Presents At Stifel 2017 Healthcare Conference - Slideshow

via: SeekingAlpha at 2017-11-16 14:06:20:000

The following slide deck was published by Akcea Therapeutics in conjunction with this Read more … read more...

Marketing applications for Akcea's volanesorsen for FCS accepted in U.S., Europe and Canada

via: SeekingAlpha at 2017-11-15 08:09:35:000

Ionis Pharmaceuticals (NASDAQ: IONS ) affiliate Akcea Therapeutics (NASDAQ: AKCA ) announces that its marketing applications in the U.S., Europe and Canada seeking approval for volanesorsen for the treatment of familial chylomicronemia syndrome (FCS) have been accepted for review. More n… read more...

Marketing applications for Akcea's volanesorsen for FCS accepted in U.S., Europe and Canada

via: SeekingAlpha at 2017-11-15 08:09:35:000

Ionis Pharmaceuticals (NASDAQ: IONS ) affiliate Akcea Therapeutics (NASDAQ: AKCA ) announces that its marketing applications in the U.S., Europe and Canada seeking approval for volanesorsen for the treatment of familial chylomicronemia syndrome (FCS) have been accepted for review. More n… read more...

Marketing applications for Akcea's volanesorsen for FCS accepted in U.S., Europe and Canada

via: SeekingAlpha at 2017-11-15 08:09:35:000

Ionis Pharmaceuticals (NASDAQ: IONS ) affiliate Akcea Therapeutics (NASDAQ: AKCA ) announces that its marketing applications in the U.S., Europe and Canada seeking approval for volanesorsen for the treatment of familial chylomicronemia syndrome (FCS) have been accepted for review. More n… read more...

Marketing applications for Akcea's volanesorsen for FCS accepted in U.S., Europe and Canada

via: SeekingAlpha at 2017-11-15 08:09:35:000

Ionis Pharmaceuticals (NASDAQ: IONS ) affiliate Akcea Therapeutics (NASDAQ: AKCA ) announces that its marketing applications in the U.S., Europe and Canada seeking approval for volanesorsen for the treatment of familial chylomicronemia syndrome (FCS) have been accepted for review. More n… read more...

Marketing applications for Akcea's volanesorsen for FCS accepted in U.S., Europe and Canada

via: SeekingAlpha at 2017-11-15 08:09:35:000

Ionis Pharmaceuticals (NASDAQ: IONS ) affiliate Akcea Therapeutics (NASDAQ: AKCA ) announces that its marketing applications in the U.S., Europe and Canada seeking approval for volanesorsen for the treatment of familial chylomicronemia syndrome (FCS) have been accepted for review. More n… read more...

Akcea launches mid-stage development of anti-hyperlipidemia candidate AKCEA-ANGPTL3-LRx

via: SeekingAlpha at 2017-11-13 17:09:04:000

Ionis Pharmaceuticals (NASDAQ: IONS ) affiliate Akcea Therapeutics (NASDAQ: AKCA ) initiates a Phase 2 program of AKCEA-ANGPTL3-Lrx in patients with rare conditions characterized by excessive levels of lipids in their blood. More news on: Ionis Pharmaceuticals, Inc., Akcea Therapeutics, … read more...

Akcea launches mid-stage development of anti-hyperlipidemia candidate AKCEA-ANGPTL3-LRx

via: SeekingAlpha at 2017-11-13 17:09:04:000

Ionis Pharmaceuticals (NASDAQ: IONS ) affiliate Akcea Therapeutics (NASDAQ: AKCA ) initiates a Phase 2 program of AKCEA-ANGPTL3-Lrx in patients with rare conditions characterized by excessive levels of lipids in their blood. More news on: Ionis Pharmaceuticals, Inc., Akcea Therapeutics, … read more...

Akcea launches mid-stage development of anti-hyperlipidemia candidate AKCEA-ANGPTL3-LRx

via: SeekingAlpha at 2017-11-13 17:09:04:000

Ionis Pharmaceuticals (NASDAQ: IONS ) affiliate Akcea Therapeutics (NASDAQ: AKCA ) initiates a Phase 2 program of AKCEA-ANGPTL3-Lrx in patients with rare conditions characterized by excessive levels of lipids in their blood. More news on: Ionis Pharmaceuticals, Inc., Akcea Therapeutics, … read more...

Akcea launches mid-stage development of anti-hyperlipidemia candidate AKCEA-ANGPTL3-LRx

via: SeekingAlpha at 2017-11-13 17:09:04:000

Ionis Pharmaceuticals (NASDAQ: IONS ) affiliate Akcea Therapeutics (NASDAQ: AKCA ) initiates a Phase 2 program of AKCEA-ANGPTL3-Lrx in patients with rare conditions characterized by excessive levels of lipids in their blood. More news on: Ionis Pharmaceuticals, Inc., Akcea Therapeutics, … read more...

Akcea launches mid-stage development of anti-hyperlipidemia candidate AKCEA-ANGPTL3-LRx

via: SeekingAlpha at 2017-11-13 17:09:04:000

Ionis Pharmaceuticals (NASDAQ: IONS ) affiliate Akcea Therapeutics (NASDAQ: AKCA ) initiates a Phase 2 program of AKCEA-ANGPTL3-Lrx in patients with rare conditions characterized by excessive levels of lipids in their blood. More news on: Ionis Pharmaceuticals, Inc., Akcea Therapeutics, … read more...

Akcea Therapeutics misses by $0.08

via: SeekingAlpha at 2017-11-06 16:15:45:000

Akcea Therapeutics (NASDAQ: AKCA ): Q3 EPS of -$0.27 misses by $0.08 . Shares +2.4% . Press Release More news on: Akcea Therapeutics, Earnings news and commentary, Stocks on the move, Healthcare stocks news, read more...

Akcea Therapeutics misses by $0.08

via: SeekingAlpha at 2017-11-06 16:15:45:000

Akcea Therapeutics (NASDAQ: AKCA ): Q3 EPS of -$0.27 misses by $0.08 . Shares +2.4% . Press Release More news on: Akcea Therapeutics, Earnings news and commentary, Stocks on the move, Healthcare stocks news, read more...

Akcea Therapeutics misses by $0.08

via: SeekingAlpha at 2017-11-06 16:15:45:000

Akcea Therapeutics (NASDAQ: AKCA ): Q3 EPS of -$0.27 misses by $0.08 . Shares +2.4% . Press Release More news on: Akcea Therapeutics, Earnings news and commentary, Stocks on the move, Healthcare stocks news, read more...

Akcea Therapeutics misses by $0.08

via: SeekingAlpha at 2017-11-06 16:15:45:000

Akcea Therapeutics (NASDAQ: AKCA ): Q3 EPS of -$0.27 misses by $0.08 . Shares +2.4% . Press Release More news on: Akcea Therapeutics, Earnings news and commentary, Stocks on the move, Healthcare stocks news, read more...

Akcea Therapeutics misses by $0.08

via: SeekingAlpha at 2017-11-06 16:15:45:000

Akcea Therapeutics (NASDAQ: AKCA ): Q3 EPS of -$0.27 misses by $0.08 . Shares +2.4% . Press Release More news on: Akcea Therapeutics, Earnings news and commentary, Stocks on the move, Healthcare stocks news, read more...

Notable earnings after Monday's close

via: SeekingAlpha at 2017-11-05 17:35:43:000

ADUS , AEL , AKCA , AMC , ANDE , APLE , APPF , ASH , ATSG , AWR , BKD , BWXT , CAR , CINR , CORE , CPE , CRC , CVGI , DPLO , DRH , ECYT , EFC , ETSY , FANG , FBP , FMC , FN , FPRX , FRGI , FRPT , GDDY , HHC , IFF , IPCC , IVR , KND , KNX , LCI , MCHP ,… read more...

Notable earnings after Monday's close

via: SeekingAlpha at 2017-11-05 17:35:43:000

ADUS , AEL , AKCA , AMC , ANDE , APLE , APPF , ASH , ATSG , AWR , BKD , BWXT , CAR , CINR , CORE , CPE , CRC , CVGI , DPLO , DRH , ECYT , EFC , ETSY , FANG , FBP , FMC , FN , FPRX , FRGI , FRPT , GDDY , HHC , IFF , IPCC , IVR , KND , KNX , LCI , MCHP ,… read more...

Notable earnings after Monday's close

via: SeekingAlpha at 2017-11-05 17:35:43:000

ADUS , AEL , AKCA , AMC , ANDE , APLE , APPF , ASH , ATSG , AWR , BKD , BWXT , CAR , CINR , CORE , CPE , CRC , CVGI , DPLO , DRH , ECYT , EFC , ETSY , FANG , FBP , FMC , FN , FPRX , FRGI , FRPT , GDDY , HHC , IFF , IPCC , IVR , KND , KNX , LCI , MCHP ,… read more...

Notable earnings after Monday's close

via: SeekingAlpha at 2017-11-05 17:35:43:000

ADUS , AEL , AKCA , AMC , ANDE , APLE , APPF , ASH , ATSG , AWR , BKD , BWXT , CAR , CINR , CORE , CPE , CRC , CVGI , DPLO , DRH , ECYT , EFC , ETSY , FANG , FBP , FMC , FN , FPRX , FRGI , FRPT , GDDY , HHC , IFF , IPCC , IVR , KND , KNX , LCI , MCHP ,… read more...

Notable earnings after Monday's close

via: SeekingAlpha at 2017-11-05 17:35:43:000

ADUS , AEL , AKCA , AMC , ANDE , APLE , APPF , ASH , ATSG , AWR , BKD , BWXT , CAR , CINR , CORE , CPE , CRC , CVGI , DPLO , DRH , ECYT , EFC , ETSY , FANG , FBP , FMC , FN , FPRX , FRGI , FRPT , GDDY , HHC , IFF , IPCC , IVR , KND , KNX , LCI , MCHP ,… read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided for free by IEX